Avalo Therapeutics (AVTX) Q4 2023 Annual Earnings
AVTX·Reported May 13, 2024·Before market open
Avalo Therapeutics reported Q4 2023 revenue of $571.0K. Diluted EPS came in at $-5.98, missed the $-1.18 consensus by $4.80.
Revenue
$571.0K
Diluted EPS
$-5.98missed by $4.80
Consensus: $-1.18
Financial Snapshot
Trailing eight quarters through Q4 2023
Q4 2023 Earnings FAQ
Common questions about Avalo Therapeutics's Q4 2023 earnings report.
Avalo Therapeutics (AVTX) reported Q4 2023 earnings on May 13, 2024 before market open.
Avalo Therapeutics reported revenue of $571.0K and diluted EPS of $-5.98 for Q4 2023.
EPS missed the consensus estimate of $-1.18 by $4.80.
You can read the 10-K periodic report (0001628280-24-013786) directly on SEC EDGAR. The filing index links above go to sec.gov.